Page last updated: 2024-12-06
fat red 7b
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
fat red 7B: lipophilic dye [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 61396 |
| CHEBI ID | 82537 |
| SCHEMBL ID | 39613 |
| SCHEMBL ID | 11876264 |
| SCHEMBL ID | 11876269 |
| MeSH ID | M0134811 |
Synonyms (78)
| Synonym |
|---|
| [(phenyl[azo-4-(phenylazo)]]-1-ethylamino-2-naphthalene |
| 1-[4-(phenylazo)-phenylazo]-2-ethylaminonaphthalene |
| typogen carmine |
| n-ethyl-1-[[4-(phenylazo)phenyl]azo]-2-naphthylamine |
| c.i. 26,050 |
| c.i. 26050 |
| lacquer red v3b |
| hexatype carmine b |
| sudanrot 7b |
| fat red 7b |
| c.i. solvent red 19 |
| 2-naphthalenamine, n-ethyl-1-[[4-(phenylazo)phenyl]azo]- |
| ceres red 7b |
| organol bordeaux b |
| nsc326202 |
| special blue x-2137 |
| n-ethyl-1-[[p-(phenylazo)phenyl]azo]-2-naphthalenamine |
| sudan red 7b |
| 6368-72-5 |
| 2-naphthylamine, n-ethyl-1-[[p-(phenylazo)phenyl]azo]- |
| wln: l66j bnunr dnunr&& cm2 |
| solvent red 019 |
| solvent red 19 |
| nsc-326202 |
| n-ethyl-1-((p-(phenylazo)phenyl)azo)-2-naphthalenamine |
| nsc 326202 |
| special blue x 2137 |
| 1-(4-phenylazo-phenylazo)-2-ethylaminonaphthalene |
| sudan 7b |
| n-ethyl-1-(4-(phenylazo)phenylazo)-2-naphthylamine |
| 2-naphthylamine, n-ethyl-1-((p-(phenylazo)phenyl)azo)- |
| brn 3534323 |
| cerven rozpoustedlova 19 [czech] |
| (phenylazo-4-phenylazo)-1-ethylamino-2-naphthalene |
| einecs 228-862-5 |
| 2-naphthalenamine, n-ethyl-1-((4-(phenylazo)phenyl)azo)- |
| n-ethyl-1-((4-(phenylazo)phenyl)azo)-2-naphthylamine |
| sudan red 7b, dye content 95 % |
| sudan red 7b, for microscopy (bot., hist.) |
| n-ethyl-1-[(4-phenyldiazenylphenyl)diazenyl]naphthalen-2-amine |
| O0096 |
| n-ethyl-1-[2-[4-(2-phenyldiazenyl)phenyl]diazenyl]-2-naphthalenamine |
| C19529 |
| AKOS024348915 |
| unii-8quh39y06p |
| cerven rozpoustedlova 19 |
| fat red |
| 2-naphthalenamine, n-ethyl-1-(2-(4-(2-phenyldiazenyl)phenyl)diazenyl)- |
| 8quh39y06p , |
| 4-16-00-00556 (beilstein handbook reference) |
| FT-0636119 |
| 2-naphthalenamine, n-ethyl-1-[2-[4-(2-phenyldiazenyl)phenyl]diazenyl]- |
| SCHEMBL39613 |
| CHEBI:82537 |
| SCHEMBL11876264 |
| SCHEMBL11876269 |
| DTXSID4064266 |
| fat red bluish |
| n-ethyl-1-((4-[phenyldiazenyl]phenyl)diazenyl)-2-naphthalenamine # |
| 1-(4-(phenylazo)-phenylazo)-2-ethylaminonaphthalene |
| (phenyl(azo-4-(phenylazo))-1-ethylamino-2-naphthalene |
| VKWNTWQXVLKCSG-ZDXBJJIESA-N |
| n-ethyl-1-((4-(phenyldiazenyl)phenyl)diazenyl)naphthalen-2-amine |
| mfcd00003904 |
| sudan red 460 |
| sudan red 462 |
| lacquer red v 3b nsc |
| sudan red 7b [iarc] |
| n-ethyl-1-(2-(4-(2-phenyldiazenyl)phenyl)diazenyl)-2-naphthalenamine |
| ci 26050 |
| sudan red 7b, analytical standard |
| n-ethyl-1-[(1e)-2-{4-[(1e)-2-phenyldiazen-1-yl]phenyl}diazen-1-yl]naphthalen-2-amine |
| n-ethyl-1-((e)-(4-((e)-phenyldiazenyl)phenyl)diazenyl)naphthalen-2-amine |
| Q27889956 |
| sudan red 7b 100 microg/ml in acetonitrile |
| Q6518814 |
| H12056 |
| AS-76183 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pellets are capable of transfering lipophilic compounds into the aqueous phase and have a high potential to increase the bioavailability of lipophilic drugs." | ( Preparation and characterization of a self-emulsifying pellet formulation. Abdalla, A; Mäder, K, 2007) | 0.34 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (16)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.10
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.10) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (6.25%) | 5.53% |
| Reviews | 1 (6.25%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||